EC Pharmacology and Toxicology

Guest Editorial Volume 13 Issue 11 - 2025

Pharmacological Aspects of Nose-to-Brain Drug Delivery Systems: Discussion on Current Commercial Outlook

Pranjal Gujarathi1, Dipak Bari2 and Chandrakantsing Pardeshi2*

1Department of Pharmacology, Vidhyadeep Institute of Pharmacy, Vidhyadeep University, Surat, Gujarat, India

2Department of Pharmaceutics, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India

*Corresponding Author: Chandrakantsing Pardeshi, Associate Professor of Pharmaceutics, Industrial Pharmacy Laboratory, Department of Pharmaceutics, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India.
Received: October 01, 2025; Published: October 21, 2025



The treatment of CNS disorders is quite challenging due to the blood-brain barrier (BBB), which hinders the therapeutic entity from reaching the brain after subsequent oral and parenteral administration. At present, nose-to-brain drug delivery has heightened interest as a promising non-invasive route that bypasses numerous obstacles, enabling more direct access via the olfactory and trigeminal neural pathways [1]. These editorial reviews the pharmacological principles of the nose-to-brain system, recent technologies, and the commercial landscape.

  1. EJ Patharapankal., et al. “Nose-to-brain (N2B) delivery: an alternative route for the delivery of biologics in the management and treatment of central nervous system disorders”. Pharmaceutics1 (2023): 66.
  2. ML Formica., et al. “On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles”. Applied Materials Today 29 (2022): 101631.
  3. CV Pardeshi and VS Belgamwar. “Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting”. Expert Opinion on Drug Delivery7 (2013): 957-972.
  4. K Xu., et al. “Nose‐to‐brain delivery of nanotherapeutics: Transport mechanisms and applications”. WIREs Nanomedicine and Nanobiotechnology2 (2024): e1956.
  5. DB Bari., et al. “Nose-to-brain delivery of self-assembled curcumin-nanocochleates for glioblastoma treatment”. Journal of Drug Delivery Science and Technology 104 (2025): 106557.
  6. R Upadhyay., et al. “Advancement in the nose-to-brain drug delivery of FDA-approved drugs for the better management of depression and psychiatric disorders”. International Journal of Pharmaceutics 667 (2024): 124866.
  7. Irving Kenneth., et al. “Intranasal and olfactory delivery devices and methods of use”. US12343489B2 (2025).
  8. W Alabsi., et al. “Nose-to-brain delivery of therapeutic peptides as nasal aerosols”. Pharmaceutics 14 (2022): 1870.
  9. Y Ge., et al. “Nasal drug delivery and nose-to-brain delivery technology development status and trend analysis: based on questionnaire survey and patent analysis”. Pharmaceutics 7 (2024): 929.
  10. M Raghav., et al. “Nose-to-brain drug delivery: Challenges and progress towards brain targeting in the treatment of neurological disorders”. Journal of Drug Delivery Science and Technology 86 (2023): 104756.
  11. S Rençber., et al. “Development of novel mucoadhesive gels containing nanoparticles for buccal administration of dexamethasone”. Brazilian Journal of Pharmaceutical Sciences 58 (2022).
  12. DB Bari and CV Pardeshi. “Monoclonal antibodies-anchored quantum dots-based delivery strategies for glioblastoma treatment: challenges and applications”. Advanced Pharmaceutical Bulletin 2 (2025): 341-358.

Chandrakantsing Pardeshi., et al. “Pharmacological Aspects of Nose-to-Brain Drug Delivery Systems: Discussion on Current Commercial Outlook”. EC Pharmacology and Toxicology  13.11 (2025): 01-03.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net